Cardinal Health vs Cencora
CAH and COR side by side, both in wholesale trade-non-durable goods. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CAH and COR compare
Cardinal Health and Cencora are about the same size, with market caps of $64.7B and $66.7B.
On earnings, Cencora is cheaper: it trades at 25.9× trailing earnings, against 35.9× for Cardinal Health.
Cardinal Health grew revenue faster over the last twelve months (10.0% versus 5.1% for Cencora).
Cencora keeps more of each dollar of sales as profit, with a net margin of 0.79% compared with 0.71% at Cardinal Health.
Both pay dividends: Cardinal Health yields 0.74% and Cencora 0.69%.
Cardinal Health scores higher on the StockData Score (16 against 14 for Cencora), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CAH | COR |
|---|---|---|
| Size and price | ||
| Market cap | $64.7B | $66.7B |
| Share price | $278.14 | $349.38 |
| Change, 1 year | 35.8% | −4.3% |
| Change, 5 years | 474% | 190% |
| Beta (5Y) | 0.46 | 0.33 |
| Employees | 64K | 51K |
| StockData Score | ||
| Total score | 16 (better) | 14 |
| Valuation score | 1 (better) | 0 |
| Growth score | 4 (better) | 3 |
| Performance score | 4 | 5 (better) |
| Health score | 3 (better) | 2 |
| Dividend score | 4 | 4 |
| Valuation | ||
| P/E | 35.9× | 25.9× (better) |
| P/S | 0.3× | 0.2× (better) |
| P/B | – | 21.9× |
| EV/EBITDA | 18.6× | 18.6× (better) |
| P/FCF | 13.2× (better) | 16.4× |
| PEG | 0.45 | – |
| FCF yield | 7.6% (better) | 6.1% |
| Fair value | $205.25 | $285.38 |
| Margin of safety | −35.5% | −22.4% (better) |
| Growth | ||
| Revenue growth (TTM) | 10.0% (better) | 5.1% |
| Revenue growth, 5Y average | 9.4% | 11.1% (better) |
| Net income growth (TTM) | 14.0% | 38.3% (better) |
| EPS growth (TTM) | 16.7% | 38.6% (better) |
| EPS growth, 5Y average | 28.3% | – |
| Profitability | ||
| Gross margin | 3.9% | 4.0% (better) |
| Operating margin | 1.0% (better) | 0.91% |
| Net margin | 0.71% | 0.79% (better) |
| FCF margin | 1.9% (better) | 1.2% |
| Return on equity | – | 104% |
| Return on invested capital | 206% (better) | 22.3% |
| Financial health | ||
| Debt / equity | – | 3.84 |
| Net debt / EBITDA | 0.97 (better) | 2.18 |
| Interest coverage | 7.9× | – |
| Current ratio | 0.88 | 0.93 (better) |
| Altman Z-score | 5.05 (better) | 4.68 |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.74% (better) | 0.69% |
| Payout ratio | 26.8% | 17.8% |
| Years of dividend growth | 17 (better) | 16 |
| Dividend growth, 5Y average | 1.0% | 5.8% (better) |
| Buyback yield | 2.3% (better) | 1.5% |
| Shareholder yield | 3.0% (better) | 2.2% |
| Ownership | ||
| Held by institutions | 88.7% | 96.1% |
| Held by insiders | 0.28% | 5.4% |
| Insider net buying, 12 months | −$61.6M | −$11.2M (better) |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 3.3% | 1.7% |
Go deeper
- CAH stock overview
- CAH income statement
- CAH valuation and score
- COR stock overview
- COR income statement
- COR valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.